Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dermalleve** was a Calgenex over-the-counter topical cream containing **hydrocortisone 1%**, a low-potency topical corticosteroid. It was introduced for symptomatic treatment of inflammatory, pruritic skin conditions including psoriasis, eczema, and seborrheic dermatitis. Hydrocortisone activates glucocorticoid receptors in the skin, suppressing inflammatory signaling and helping reduce erythema, irritation, and itch. The product also incorporated non-drug skin conditioners and emollients. Publicly available information is historical; Dermalleve is distinct from the currently marketed similarly spelled product Dermeleve.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermalleve.